Our Services
Medical Information
Helpful Resources
Published on: 2/1/2026
GLP-1 weight loss meds can lower libido in some people by affecting brain reward pathways, shifting hormones during weight loss, reducing energy and nutrition, causing GI discomfort, and interacting with emotional factors, and many notice improvement as the body adjusts or with dose and lifestyle changes. There are several factors to consider; see below for practical steps, what to discuss with your clinician, and other causes to rule out, and do not stop your medication without medical guidance because abrupt changes can destabilize blood sugar and lead to weight regain.
GLP-1 medications like semaglutide and tirzepatide have helped millions of people lose weight and improve blood sugar control. But as their use becomes more common, some users are noticing an unexpected change: a drop in sexual desire.
If you've been wondering whether your weight loss medication could be linked to changes in your libido, you're not imagining things. While this side effect isn't always talked about openly, it is increasingly recognized by clinicians and researchers.
Below, we'll explore how GLP-1 medications may affect sexual desire, the most common low libido causes, and what you can do if this side effect is affecting your quality of life.
GLP-1 receptor agonists are medications originally developed to treat type 2 diabetes. They are now widely prescribed for weight loss. These drugs work by mimicking a natural hormone called glucagon-like peptide-1 (GLP-1), which:
Common GLP-1 medications include semaglutide and tirzepatide, though brand names vary.
While their benefits are well documented, GLP-1 drugs influence multiple systems in the body—including the brain and hormones—which may help explain changes in libido.
Low libido is not always listed as a primary side effect, but emerging evidence and patient reports suggest a possible connection. Sexual desire is complex and influenced by physical, hormonal, psychological, and emotional factors. GLP-1 medications may affect several of these at the same time.
This does not mean everyone will experience changes in libido. Many people do not. But if it happens, it's worth understanding why.
GLP-1 drugs act on the brain's reward system. The same neural pathways involved in hunger and food enjoyment are also involved in pleasure, motivation, and sexual interest.
For some people, this can mean:
This doesn't indicate anything is "wrong" with you—it reflects how interconnected these systems are.
Rapid or significant weight loss can temporarily alter hormone levels, including:
Hormonal shifts are among the most common low libido causes in both men and women. In some cases, the body needs time to adjust to a new weight and metabolic state.
Eating much less than before can lead to:
When the body is low on energy, sexual desire often drops. This is a protective mechanism, not a personal failure.
Nausea, bloating, or stomach discomfort—common GLP-1 side effects—can make intimacy feel unappealing. Even mild, ongoing discomfort can affect desire over time.
Weight loss can bring up complex emotions, including:
In some individuals, weight loss may reduce libido because sexual interest was previously tied to emotional coping, reassurance, or stress relief.
If past experiences may be playing a role in your current symptoms, a free Sexual Trauma symptom checker can help you understand whether this could be a contributing factor worth exploring with a professional.
It's important not to assume your medication is the only factor. Low libido often has multiple contributing causes, such as:
GLP-1 medications may unmask an underlying issue rather than directly cause the problem.
In many cases, no.
For some people, libido returns after:
For others, low libido may persist and require a more individualized approach. This is why it's important not to ignore the symptom—especially if it affects your emotional wellbeing or relationships.
Note when the change started and whether it coincided with:
Patterns can be helpful for your doctor.
Even with a reduced appetite, your body still needs:
Poor nutrition is a frequent and overlooked low libido cause.
Chronic stress and lack of sleep strongly suppress sexual desire. Simple improvements in sleep quality can make a meaningful difference.
Low libido is a medical and biological issue—not a reflection of attraction or commitment. Clear communication can reduce misunderstandings and emotional strain.
This is essential.
A healthcare provider can:
If your symptoms are severe, worsening, or accompanied by depression, hormonal symptoms, or physical changes, speak to a doctor as soon as possible.
Do not stop or change your medication without medical guidance.
Abruptly stopping GLP-1 therapy can lead to:
A doctor can help you weigh the benefits and side effects and decide on the safest next step.
GLP-1 medications are powerful tools for improving metabolic health, but they can affect more than appetite and weight. Changes in libido are real, valid, and increasingly recognized.
Low libido causes are often multi-layered, involving hormones, brain chemistry, nutrition, emotional health, and life circumstances. The good news is that most causes are treatable, especially when addressed early.
You are not alone—and you don't have to guess what's going on.
If something feels off, listen to your body, gather information, and speak to a doctor about any symptoms that concern you or could be serious. Your health includes your sexual wellbeing, and it deserves attention too.
(References)
* Al-Rubeaan A, Al-Hussein M, As-Sanie A, Al-Bander B, Al-Hadi D, Al-Ramadan A, Al-Shaikh A, Al-Qattan H, Al-Shorouqi M, Al-Hamad K. Effects of glucagon-like peptide-1 receptor agonists on sexual function: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023 Jun 20;14:1210878. doi: 10.3389/fendo.2023.1210878. PMID: 37408891; PMCID: PMC10317072.
* Duca Y, Giannetta E, Lenzi A, Basciani S. Incretin-based therapies and male sexual function: a systematic review. J Endocrinol Invest. 2023 Aug;46(8):1501-1509. doi: 10.1007/s40618-023-02058-2. Epub 2023 May 10. PMID: 37166567.
* Galiè M, Cella S, Mazzone E, Fabbri A, Rochira V. Glucagon-Like Peptide-1 (GLP-1) and Sexual Function: A Narrative Review. J Clin Med. 2023 May 17;12(10):3539. doi: 10.3390/jcm12103539. PMID: 37240871; PMCID: PMC10220610.
* Duca Y, Santoro A, Sposato G, Aversa A, Basciani S. SGLT2 inhibitors and GLP-1 receptor agonists in erectile dysfunction: A narrative review. J Endocrinol Invest. 2024 Jan;47(1):15-22. doi: 10.1007/s40618-023-02200-5. Epub 2023 Nov 21. PMID: 37989914.
* Sposato G, Lenzi A, Aversa A, Duca Y. Impact of antihyperglycemic drugs on male sexual function in patients with type 2 diabetes mellitus: a comprehensive review. J Endocrinol Invest. 2023 Apr;46(4):615-627. doi: 10.1007/s40618-022-01962-9. Epub 2022 Dec 13. PMID: 36512398.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.